List view / Grid view
A complete response letter for Eli Lilly's accelerated approval submission…
A complete response letter for Eli Lilly's accelerated approval submission of donanemab for early Alzheimer's has been issued by the US Food and Drug Administration (FDA).
Full study results of Eisai’s Phase III Alzheimer's study suggest…
Full study results of Eisai’s Phase III Alzheimer's study suggest lecanemab could slow disease progression.
In a study of 94 patients with mild-to-moderate Alzheimer’s disease,…
In a study of 94 patients with mild-to-moderate Alzheimer’s disease, rotigotine improved frontal lobe executive function and enabled patients to independently perform daily activities.
